Accelerō Bioanalytics GmbH, a GLP bioanalytical ligand binding assay service provider establishing an innovative business and marketing paradigm, announced today that it has entered into a collaboration agreement with LPT Laboratory of Pharmacology and Toxicology GmbH & Co KG (
This cooperation opens LPT the opportunity to access Accelerō Bioanalytics´ GLP compliant Real-Time qPCR assay portfolio. The recently acquired ViiA™ 7 qPCR system provides an ideal extension to LPT´s in-house bioanalytical services. As Accelerō Bioanalytics is one of the first to offer Real-Time qPCR assays in a regulatory context, this partnership now brings LPT into the position to offer a broader range of bioanalytical assays for its customers´ preclinical drug development pipelines.
Accelerō Bioanalytics in turn will promote LPT´s extensive pharmacological and toxicological service portfolio. According to the principle: “all from one hand”, this partnership prepares a beneficial complete preclinical drug development line from in vivo research to concomitant PK/PD bioanalysis.
LPT Laboratory of Pharmacology and Toxicology GmbH & Co KG is one of
Accelero Bioanalytics GmbH was established in September 2011 right in the heart of
Accelero Bioanalytics is determined to become a preferred partner for the Biotech and Pharma business in the field of investigative new drugs based on nucleic acid chemistry.
|< Prev||Next >|